Search Results - "Dearling, Jason"

Refine Results
  1. 1

    Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics by Dammes, Niels, Goldsmith, Meir, Ramishetti, Srinivas, Dearling, Jason L. J., Veiga, Nuphar, Packard, Alan B., Peer, Dan

    Published in Nature nanotechnology (01-09-2021)
    “…The successful in vivo implementation of gene expression modulation strategies relies on effective, non-immunogenic delivery vehicles. Lipid nanoparticles are…”
    Get full text
    Journal Article
  2. 2

    Molecular imaging in nanomedicine – A developmental tool and a clinical necessity by Dearling, Jason L.J., Packard, Alan B.

    Published in Journal of controlled release (10-09-2017)
    “…The development of nanomedicines presents the potential to deliver more potent drugs targeted more specifically to the site(s) of disease than is currently…”
    Get full text
    Journal Article
  3. 3

    Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases by Dearling, Jason L. J., van Dam, Ellen M., Harris, Matthew J., Packard, Alan B.

    Published in EJNMMI research (25-02-2021)
    “…Background A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual…”
    Get full text
    Journal Article
  4. 4

    Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM by Dearling, Jason L.J, Packard, Alan B

    Published in Nuclear medicine and biology (01-04-2010)
    “…Abstract Cu(II)-ATSM continues to be investigated, both in the laboratory and in the clinic, as a tumor hypoxia imaging agent. However, meaningful…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    The Ionic Charge of Copper-64 Complexes Conjugated to an Engineered Antibody Affects Biodistribution by Dearling, Jason L. J, Paterson, Brett M, Akurathi, Vamsidhar, Betanzos-Lara, Soledad, Treves, S. Ted, Voss, Stephan D, White, Jonathan M, Huston, James S, Smith, Suzanne V, Donnelly, Paul S, Packard, Alan B

    Published in Bioconjugate chemistry (15-04-2015)
    “…The development of biomolecules as imaging probes requires radiolabeling methods that do not significantly influence their biodistribution. Sarcophagine (Sar)…”
    Get full text
    Journal Article
  8. 8

    Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics by Dearling, Jason L J, Daka, Ala, Veiga, Nuphar, Peer, Dan, Packard, Alan B

    Published in Inflammatory bowel diseases (01-03-2016)
    “…Positron emission tomography combined with a specific probe presents the ability to noninvasively assess inflammatory bowel disease. We previously reported…”
    Get full text
    Journal Article
  9. 9

    Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection by Daly, Kevin P, Dearling, Jason L J, Seto, Tatsuichiro, Dunning, Patricia, Fahey, Frederic, Packard, Alan B, Briscoe, David M

    Published in Transplantation (01-09-2015)
    “…Positron emission tomography (PET) has the potential to be a specific, sensitive and quantitative diagnostic test for transplant rejection. To test this…”
    Get full text
    Journal Article
  10. 10

    Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo by Celik, Aybuke, Orfany, Arzoo, Dearling, Jason, del Nido, Pedro J., McCully, James D., Bakar-Ates, Filiz

    Published in Biomedicine & pharmacotherapy (01-05-2023)
    “…Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies…”
    Get full text
    Journal Article
  11. 11

    Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas by EL EMIR, Ethaar, QURESHI, Uzma, DEARLING, Jason L. J, BOXER, Geoffrey M, CLATWORTHY, Innes, FOLARIN, Amos A, ROBSON, Mathew P, NAGL, Sylvia, KONERDING, Moritz A, PEDLEY, R. Barbara

    Published in Cancer research (Chicago, Ill.) (15-12-2007)
    “…Solid tumors have a heterogeneous pathophysiology, which directly affects antibody-targeted therapies. Here, we consider the influence of selected tumor…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Imaging cancer using PET — the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody by Dearling, Jason L.J., Voss, Stephan D., Dunning, Patricia, Snay, Erin, Fahey, Frederic, Smith, Suzanne V., Huston, James S., Meares, Claude F., Treves, S. Ted, Packard, Alan B.

    Published in Nuclear medicine and biology (2011)
    “…Use of copper radioisotopes in antibody radiolabeling is challenged by reported loss of the radionuclide from the bifunctional chelator used to label the…”
    Get full text
    Journal Article
  15. 15

    A Sensitive Method for the Measurement of Copper at Trace Levels Using an HPLC-Based Assay by Dearling, Jason L J, Packard, Alan B

    Published in Current radiopharmaceuticals (01-04-2017)
    “…Measurement of trace metal contamination is critical in the production of radiometals, such as 64Cu, for protein labeling. ICP-MS provides these data with high…”
    Get more information
    Journal Article
  16. 16

    Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships by Dearling, Jason L J, Lewis, Jason S, Mullen, Gregory E D, Welch, Michael J, Blower, Philip J

    Published in Journal of biological inorganic chemistry (01-03-2002)
    “…Copper(II) bis(thiosemicarbazone) complexes labelled with Cu-60/62/64 are useful radiopharmaceuticals for imaging blood flow and hypoxic tissues in vivo. The…”
    Get full text
    Journal Article
  17. 17

    Combining Radioimmunotherapy with Antihypoxia Therapy 2-Deoxy-d-Glucose Results in Reduction of Therapeutic Efficacy by DEARLING, Jason L. J, QURESHI, Uzma, BEGENT, Richard H. J, PEDLEY, R. Barbara

    Published in Clinical cancer research (15-03-2007)
    “…Purpose: The efficacy of solid tumor radioimmunotherapy is reduced by heterogeneous tumor distribution of the radionuclide, with dose mainly deposited in the…”
    Get full text
    Journal Article
  18. 18

    Targeted Imaging of Ewing Sarcoma in Preclinical Models Using a 64Cu-Labeled Anti-CD99 Antibody by O'NEILL, Allison F, DEARLING, Jason L. J, YUCHUAN WANG, TUPPER, Tanya, YANPING SUN, ASTER, Jon C, CALICCHIO, Monica L, PEREZ-ATAYDE, Antonio R, PACKARD, Alan B, KUNG, Andrew L

    Published in Clinical cancer research (01-02-2014)
    “…Ewing sarcoma is a tumor of the bone and soft tissue characterized by diffuse cell membrane expression of CD99 (MIC2). Single-site, surgically resectable…”
    Get full text
    Journal Article
  19. 19

    Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake by Dearling, Jason L.J, Flynn, Aiden A, Qureshi, Uzma, Whiting, Stephen, Boxer, Geoffrey M, Green, Alan, Begent, Richard H.J, Pedley, R. Barbara

    Published in Nuclear medicine and biology (01-11-2009)
    “…Abstract Introduction Radioimmunotherapy (RIT) has been shown to be more effective against solid tumor micrometastases, possibly due to an inverse relationship…”
    Get full text
    Journal Article
  20. 20